Modified antigen binding molecules with altered cell signaling activity

Details for Australian Patent Application No. 2006290433 (hide)

Owner GlycArt Biotechnology AG

Inventors Umana, Pablo; Mossner, Ekkehard

Agent Davies Collison Cave

Pub. Number AU-B-2006290433

PCT Pub. Number WO2007/031875

Priority 60/711,454 26.08.05 US

Filing date 25 August 2006

Wipo publication date 22 March 2007

Acceptance publication date 7 June 2012

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 (2006.01) Antineoplastic agents

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/13 (2006.01) Mutation or genetic engineering - Immunoglobulins

Event Publications

10 April 2008 PCT application entered the National Phase

  PCT publication WO2007/031875 Priority application(s): WO2007/031875

7 June 2012 Application Accepted

  Published as AU-B-2006290433

23 August 2012 Alteration of Name

  The name of the applicant has been altered to Roche GlycArt AG 2007

4 October 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006290435-Modulation of immunostimulatory properties of short interfering ribonucleic acid (siRNA) by nucleotide modification

2006290431-Image enhancement and compression